Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

Table 2

Clinical characteristics in patients who experienced a relapse.

Cause of discontinuation	Relapses (n = 12)
	CR (n = 3)	SD/PD (n = 2)	AEs (n = 7)
Age
<65 years	3	2	3
>65 years	0	0	4
Sex
Men	2	1	2
Women	1	1	5
BRAF status
Mutant	2	1	3
Wild type	1	1	4
First-line treatment
Yes	1	1	3
No	2	1	4
Prior ipilimumab
Yes	2	0	3
No	1	2	4
Prior BRAF ± MEK inhibitor
Yes	1	1	2
No	2	1	5
Radiotherapy while on treatment
Yes	2	0	2
No	1	2	5
TOT
<12 months	0	1	5
>12 months	3	1	2
Relapse site
Known sites	1	1	4
New lesions	2	1	3